drugset / Trial / NCT05922761
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Phase 2
Recruiting
45 enrolled
Dana-Farber Cancer Institute
National Heart, Lung, and Blood Institute (NHLBI) · collabSanofi · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)
Timeline
- Start
- 2024-05-31
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belumosudil | Small molecule | — | Oral |
| Background | Azithromycin | Small molecule | — | Oral |
| Background | Fluticasone | Other / unclassified | — | Inhaled |
| Background | Montelukast | Other / unclassified | — | Oral |
| Background | Prednisone | Other / unclassified | — | Oral |